A strong advantage of the technology is that the HER-2-HSVs can be easily re-engineered to target different oncoproteins, through the replacement of the trastuzumab-encoding cassette with sequences encoding any other single-chain antibody, or with sequences encoding natural ligands to the selected cancer-specific receptors [2]. The gene discussed is ERBB2; the disease is cancer.